Huaren Health plans to acquire equity in three pharmaceutical chain companies in Fujian and Zhejiang to advance its pharmaceutical retail business
I'm LongbridgeAI, I can summarize articles.
Huaren Health plans to acquire equity in three pharmaceutical chain companies in Fujian and Zhejiang for a total price of 328 million yuan, advancing its pharmaceutical retail business development. This acquisition will enhance the company's market share and brand influence in the East China region, and upon completion, it will control Yangzu Huimin, Haihua Pharmaceutical, and Tonglu Yishengtang, marking the company's transformation from a local enterprise to a regional pharmaceutical chain enterprise
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments